Cross-country measures for monitoring epilepsy care

被引:21
作者
Begley, Charles E.
Baker, Gus A.
Beghi, Ettore
Butler, James
Chisholm, Daniel
Langfitt, John T.
Levy, Pierre
Pachlatko, Christoph
Wiebe, Samuel
Donaldson, Karen Lee
机构
[1] Univ Texas, Hlth Sci Ctr, Sch Publ Hlth, Houston, TX 77030 USA
[2] Univ Liverpool, Div Neurosci, Liverpool L69 3BX, Merseyside, England
[3] Ist Ric Farmacol Mario Negri, Milan, Italy
[4] Univ Stellenbosch, Dept Neurol, Johannesburg, South Africa
[5] WHO, Dept Mental Hlth & Subst Abuse, CH-1211 Geneva, Switzerland
[6] Univ Rochester, Sch Med, Dept Neurol, Rochester, NY 14627 USA
[7] Univ Paris 09, Paris, France
[8] Foothills Med Ctr, Div Neurol, Calgary, AB, Canada
[9] Epilepsy Act, Leeds, W Yorkshire, England
关键词
healthcare; evaluation; international; survey;
D O I
10.1111/j.1528-1167.2007.00981.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Purpose: The International League Against Epilepsy (ILAE) Commission on Healthcare Policy in consultation with the World Health Organization (WHO) examined the applicability and usefulness of various measures for monitoring epilepsy healthcare services and systems across countries. The goal is to provide planners and policymakers with tools to analyze the impact of healthcare services and systems and evaluate efforts to improve performance. Methods: Commission members conducted a systematic literature review and consulted with experts to assess the nature, strengths, and limitations of the treatment gap and resource availability measures that are currently used to assess the adequacy of epilepsy care. We also conducted a pilot study to determine the feasibility and applicability of using new measures to assess epilepsy care developed by the WHO including Disability-Adjusted Life Years (DALYs), responsiveness, and financial fairness. Results: The existing measures that are frequently used to assess the adequacy of epilepsy care focus on structural or process factors whose relationship to outcomes are indirect and may vary across regions. The WHO measures are conceptually superior because of their breadth and connection to articulated and agreed upon outcomes for health systems. However, the WHO measures require data that are not readily available in developing countries and most developed countries as well. Conclusion: The epilepsy field should consider adopting the WHO measures in country assessments of epilepsy burden and healthcare performance whenever data permit. Efforts should be made to develop the data elements to estimate the measures.
引用
收藏
页码:990 / 1001
页数:12
相关论文
共 46 条
[41]  
Valentine NB., 2003, Health systems performance assessment: debates, methods and empiricism
[42]  
Valentine NB, 2000, GPE DISCUSSION PAPER, V22
[43]   The prevalence and treatment gap in epilepsy in China - An ILAE/IBE/WHO study [J].
Wang, WZ ;
Wu, JZ ;
Wang, DS ;
Dai, XY ;
Yang, B ;
Wang, TP ;
Yuan, CL ;
Scott, RA ;
Prilipko, LL ;
de Boer, HM ;
Sander, JW .
NEUROLOGY, 2003, 60 (09) :1544-1545
[44]  
*WHO INT BUR EP IN, 2005, EP CAR WORLD 2005
[45]   Clinically important change in quality of life in epilepsy [J].
Wiebe, S ;
Matijevic, S ;
Eliasziw, M ;
Derry, PA .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2002, 73 (02) :116-120
[46]  
2005, S AFRICAN HLTH REV